Abstract
To summarize distinct clinical characteristics and prognoses associated with and validate the novel hematologic response criteria in Chinese light-chain amyloidosis patients with a difference between involved and uninvolved free light chain (dFLC) < 50 mg/L. We retrospectively compared clinical features and outcomes between patients in the dFLC < 50 mg/L group (n = 74) and the ≥ 50 mg/L group (n = 248). Patients with dFLC < 50 mg/L presented less frequent and less severe cardiac involvement, but higher renal involvement. Additionally, more patients in the dFLC < 50 mg/L group showed intact immunoglobulin monoclonal protein and high immunoglobulin monoclonal protein levels. Moreover, patients in the dFLC < 50 mg/L group had significantly superior progression-free survival (PFS; not reached vs. 16.0 months; p < 0.001) and overall survival (OS; not reached vs. 41.0 months; p < 0.001) as compared with those in the dFLC ≥ 50 mg/L group. Furthermore, we confirmed that achieving complete response (CR) or low dFLC partial response (PR) predicted better OS in patients with initial dFLC ≥ 20 mg/L (not reached vs. 19 months; p = 0.005). Patients with initial dFLC < 50 mg/L represented distinct clinical manifestations and outcomes. Achieving CR or low dFLC PR might represent potential therapy goals allowing better survival and organ response in patients with dFLC between 20 and 50 mg/L.
Similar content being viewed by others
References
Kastritis E, Dimopoulos MA (2016) Recent advances in the management of AL amyloidosis. Br J Haematol 172(2):170–186. https://doi.org/10.1111/bjh.13805
Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, Hayman SR, Buadi FK, Leung N, Zeldenrust SR, Ramirez-Alvarado M, Clark RJ, Kyle RA, Rajkumar SV, Gertz MA (2010) Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 116(24):5126–5129. https://doi.org/10.1182/blood-2010-06-290668
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30(9):989–995. https://doi.org/10.1200/jco.2011.38.5724
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol Off J Am Soc Clin Oncol 30(36):4541–4549. https://doi.org/10.1200/jco.2011.37.7614
Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G (2012) Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26(11):2317–2325. https://doi.org/10.1038/leu.2012.100
Sidana S, Tandon N, Dispenzieri A, Gertz M, Buadi F, Lacy M, Dingli D, Fonder A, Hayman S, Hobbs M, Gonsalves W, Hwa Y, Kapoor P, Kyle R, Leung N, Go R, Lust J, Russell S, Zeldenrust S, Rajkumar S, Kumar S (2017) Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia 32(3):729–735
Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G (2017) Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood 130(5):625–631
Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, Ho A, Hegenbart U, Schönland S (2017) AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood 130(5):632–642
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79(4):319–328. https://doi.org/10.1002/ajh.20381
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The study was approved by the Peking Union Medical College Hospital Ethic’s Committee.
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Qiu, Y., Zhang, Cl., Shen, Kn. et al. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels. Ann Hematol 97, 2465–2470 (2018). https://doi.org/10.1007/s00277-018-3460-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-018-3460-0